Novo Nordisk offers diabetes drug Ozempic for steep cash discount
A box of novo Nordisk on March 8, 2024 at a pharmacy in London.
Hollie Adams | Reuters
Novo Nordisk On Monday, drug producers faced political pressure on prices in the country, because of the cash payment to the patients who pay the toll records of the diabetes therapy Ozempic’i less than half of the monthly list price, he said.
Patients can pay $ 499 in cash per month for three doses of algae. The price of the drug can receive the official website of the drug, Novo Nordisk’s patient assistance program and the company’s recently released consumer through platforms, including platforms, including the online pharmacy, and the second sends the injection directly to patients’ homes.
According to the Novo Nordisk version, the drug -saving company Goodrx will also offer Özempic and weight loss equivalent Wegovy for $ 499 per month and offers discounts in more than 70,000 pharmacies throughout the country.
Novo Nordisk’s cash payment proposal will expand access to appropriate type 2 diabetes patients without insurance for weekly injection. In March, the company began to offer Wegovy for half of the list price to the Americans who pay cash.
OzlemPic’s list price before insurance and other discounts is almost $ 1,350 per month, and in recent years, political and public reputation has often been the target. The new proposal came after President Donald Trump sent separate letters to Novo Nordisk and 16 other drug producers in July, and urged them to take steps to reduce the pharmaceutical prices in the United States to reduce them between other proposed actions, and urged them directly to adopting models that sell drugs to consumers or businesses.
Efforts aim to make Özempic and Wegovy usable for more people, while patients aim to make patients use branded medicine rather than cheaper compound imitations. These drugs exploded in popularity during a US famine, which is currently dissolved in the Semaglluid of Novo Nordisk, an active ingredient in both drugs.
“Even though it covers well in the United States, let’s not forget that there are some patients who pay for this vital medicine,” Ozempic said. “Even a single patient feels the need to return to potentially insecure and unapproved knockout alternatives, this is too much.”
Hand Lilly Similarly, it moved to reduce the price of popular obesity and diabetes drugs for patients who pay cash. The two companies are struggling to dominate the market for GLP-1s that mimic certain bowel hormones to suppress appetite and regulate blood sugar.
